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Has Stroke Shifted From Hemorrhagic to
Ischemic in China?
To the Editor:
In China, which has the largest population and greatest number of
stroke victims in the world, data concerning stroke epidemiology are
very limited. Guidelines of stroke prevention and management
designed for Chinese were tailored, to a considerable degree,
according to the epidemiological, etiological and clinical profiles
mirrored from western populations. The higher morbidity and
mortality of stroke in Chinese further bulks the need of nationwide
epidemiological data for establishing population specialized strate-
gies for stoke prevention and management.
We read with great interest the study by Jiang et al concerning
the stroke incidence and trends in 3 large cities in China.1 It was
shown that incidence of intracranial hemorrhage (ICH) decreased
significantly at an annual rate of 12.0% in Beijing, 4.4% in
Shanghai, and 7.7% in Changsha; at the time, incidence of
ischemic stroke (IS) increased in Beijing (5.0% per year) and
Shanghai (7.7%) during the 1990s. As reasoning this opposite
trends of ischemic and hemorrhagic stroke, the authors wrote:
These (lifestyle) changes may have resulted in increased
prevalence of obesity, hypertension, diabetes, and hypercho-
lesterolemia in Chinese populations and may also help explain
the increasing trend of IS as observed in this study. Uncon-
trolled hypertension and high prevalence of smoking might
partially explain the hemorrhagic stroke predominance among
Chinese in the past, and the increasing awareness of hyperten-
sion control and decrease in cigarette smoking may have
contributed to its decrease in the past decade.
These explanations are ridiculous because it means hypertension
and other risk factors were increasing when interpreting the
trends of IS, while these risk factors were controlled and
decreasing when interpreting the trends of ICH. Furthermore,
well-designed large epidemiological studies indicated prevalence
of cigarette smoking was increasing in the 1980s and 1990s,2 and
percentage of smokers contemplating quitting was low in China.3
The incidence of hypertension and diabetes mellitus were also
increased throughout the 1990s in China.4,5 Under these circum-
stances, it is rather arbitrary to interpret the 12% annual decrease
of ICH incidence detected in this study as a result of some
underlying changes of risk factors in Chinese population.
On the other hand, the results that IS increased and ICH
decreased during 1990s can be more reasonably explained by the
misclassification of stroke patients, especially during the early
days of this study when CT and MRI scans were less available.
In the absence of neuroimaging results, IS may be misclassified
as ICH and vice versa. This study did not provide substantive
classification criteria applied at time of stroke onset. The
Atherosclerosis Risk in Communities (ARIC) criteria for stroke
diagnosis and classification used in this study were published
many years after the initiation of the study.6 In the ARIC study,
the rate of cases with CT scan is higher (84%), and stroke
patients were possibly classified as definite cerebral infarction or
definite ICH only when autopsy results or CT/MRI scans were
available. For stroke patients without neuroimaging or autopsy
results, a probable classification was made. When a stroke case
was equivocal, it was classified following the hierarchy of ICH,
subarachnoid hemorrhage, embolic brain infarction and throm-
botic brain infarction. This indicates that equivocal cases were
more probably classified as ICH than as IS. This arbitrary
allocation will undoubtedly increase the possibility of IS being
misclassified as ICH especially in patients without CT or MRI
scans. Many patients who had been diagnosed in the early days
of this study (eg, 50% of the patients diagnosed in 1991 in
Shanghai) did not have a CT or MRI scan. For these patients ICH
may be overdiagnosed.
In a large multicenter collaborative study which included
Beijing and Shanghai as this study did, Zhang and colleagues
showed proportion of clinically diagnosed7 ICH in total stroke
was increased gradually during the early years of the 1990s
(which are contrary to the results of this study), a time when
clinical application of CT and MRI was booming in mainland
China. But when ratio of patients with CT scan reached a
satisfying 85% after 1996, proportion of ICH kept considerably
equivalent over years. These results indicate that inconsistency in
stroke classification related to increasing use of CT/MRI scan
may be a prominent obstruction in evaluating the temporal trends
of stokes components.
This article provides valuable information of stroke incidence
in urban China. However, because of significant design flaw and
lack of valid criteria for stroke classification, the conclusion that
the decreased ICH and increased IS was caused by underlying
changes of risk factors in Chinese populations is misleading.
Gelin Xu, MD
Xinfeng Liu, MD
Department of Neurology
Jinling Hospital
Nanjing University School of Medicine
Nanjing, Jiangsu Province, China
1. Jiang B, Wang WZ, Chen H, Hong Z, Yang QD, Wu SP, Du XL, Bao
QJ. Incidence and trends of stroke and its subtypes in China: results from
three large cities. Stroke. 2006;37:63–68.
2. Yang G, Fan L, Tan J, Qi G, Zhang Y, Samet JM, Taylor CE, Becker K,
Xu J. Smoking in China: findings of the 1996 National Prevalence
Survey. JAMA. 1999;282:1247–1253.
3. Yang G, Ma J, Chen A, Zhang Y, Samet JM, Taylor CE, Becker K.
Smoking cessation in China: findings from the 1996 national prevalence
survey. Tob Control. 2001;10:170–174.
4. Ueshima H, Zhang XH, Choudhury SR. Epidemiology of hypertension in
China and Japan. J Hum Hypertens. 2000;14:765–769.
5. Chan JC, Ng MC, Critchley JA, Lee SC, Cockram CS. Diabetes mel-
litus–a special medical challenge from a Chinese perspective. Diabetes
Res Clin Pract. 2001;54:S19–S27.
6. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG,
Howard G, Copper LS, Shahar E. Stroke incidence and survival among
middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in
Communities (ARIC) cohort. Stroke. 1999;30:736–743.
7. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, Huang YN,
Chen J, Wu YF; Collaborative Group of China Multicenter Study of
Cardiovascular Epidemiology. Proportion of different subtypes of stroke
in China. Stroke. 2003;34:2091–2096.
Response:
We thank Drs Xu and Liu for their interest in our recent publication
on the stroke trends in 3 cities of China,1 and we reply to clarify their
questions about our stroke diagnostic criteria and classification in our
study and provide some further information regarding our study that we
could not include in the original report because of the space limitation.
However, we believe what we observed in our study was real, and our
inference of the shift from hemorrhage to ischemic stroke pattern in
China was correctly drawn.
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The criteria for stroke diagnosis and classification were similar
to those used in the Atherosclerosis Risk in Communities (ARIC)
Study, both of which were adapted from published criteria from
the National Survey of Stroke.2 Minor modifications were made
to facilitate the field data collection in China. The major
differences between the criteria used in these 2 studies,1,3 other
than languages, included: (1) “unilateral numbness of 2 or more
body parts” was regarded as a major symptom in our study but a
minor symptom in the ARIC study; (2) in the ARIC Study, a
hierarchical case definition was used for the rare situation where
the cases met criteria for 2 different diagnostic categories. In our
study, we defined such cases as “undetermined”, even for cases
with CT/MRI information. Conversely, cases only with neuro-
imaging data without clinical symptoms and signs were ex-
cluded. As in many other epidemiological studies, misclassifica-
tions were expected, but diagnostic errors should be few.
We shared Dr Xu et al’s concern that 10% of the stroke
subtypes were classified based on clinical examinations. This
was true for the first several years of follow-up. CT/MRI
technologies have become readily available in Beijing and
Shanghai (90%) since mid-1990s. Further, the high hospital-
ization rate and high quality medical service in these large cities
should have to some extent alleviated such a concern. As noted
by Dr Xu et al, ICH in total stroke gradually increased in the
study by Zhang et al in early 1990s.4 However, CT use was
slightly lower in that study compared to ours, and the increasing
trend of ICH in total stroke stopped since 1996 when CT was
used in 85% of their case diagnoses.1,4
We believe that the trend we observed in our study reflects the
changes of stroke incidence and composition in our study
populations. Further, our observation was consistent with the
findings from the MONICA study in Beijing during 1984 to
1999.5 However, our potential explanations are speculative and
we have made it clear in our discussion. More studies are needed
to confirm our findings in both urban and rural Chinese popula-
tions and to find out the reasons underlying these changes.
Bin Jiang, MD, MPH
Wen-zhi Wang, MD
Department of Neuroepidemiology
Beijing Neurosurgical Institute
Beijing, PR China
1. Jiang B, Wang WZ, Chen H, Hong Z, Yang QD, Wu SP, Du XL, Bao
QJ. Incidence and trends of stroke and its subtypes in China: results from
three large cities. Stroke. 2006;37:63–68.
2. The National Survey of Stroke. National Institute of Neurological and
Communicative Disorders and Stroke. Stroke. 1981;12 (suppl 1):I1–I91.
3. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG,
Howard G, Copper LS, Shahar E. Stroke incidence and survival among
middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in
Communities (ARIC) cohort. Stroke. 1999;30:736–743.
4. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, Huang YN,
Chen J, Wu YF. Proportion of different subtypes of stroke in China.
Stroke. 2003;34:2091–2096.
5. Wang WH, Zhao D, Wu GX, Liu J, Liu S, Qin LP, Wu ZS. Trend
analyses in the incidence of acute intracerebral hemorrhage events and
acute cerebral infarction events in urban areas in Beijing. Chin J Epi-
demiol. 2002;23:352–355 (in Chinese).
Referral Bias May Underestimate Number of
Very Elderly Patients Eligible for rtPA
To the Editor:
We read with interest the article by Berrouschot and col-
leagues on the outcome and complications of intravenous (IV)
thrombolysis with recombinant tissue plasminogen activator
(rtPA) in stroke patients aged 80 years.1 Although randomiza-
tion of patients in this age group into the ongoing IST-3 trial will
expand the evidence base for treatment in patients aged 80
years, both within 3 hours and 3 to 6 hours of onset, most active
thrombolysis centers receive referrals for older patients who
currently fall outside licensing restrictions in Europe on the basis
of age alone. Treatment is felt by many to be justified on the
basis of observational data and the small amount of randomized
controlled trial data.2 There is sparse information on numbers
and source of referral for the elderly in the thrombolysis
literature.
We undertook a prospective log of all referrals to our unit
for thrombolysis over a 12-month period (July 2004 through
June 2005). Of 188 referrals, 43/188 (23%) were patients aged
80 years. Excluding 7 patients aged 80, who would be
eligible for thrombolysis on the basis of current licensing,
36/188 (19%) would have been ineligible for treatment only
on the basis of age. Our unit has no age limit on treatment
within 3 hours provided all other criteria are satisfied, the
patient or their representative is in agreement with a treatment
decision, and with the proviso that all treated patients are
registered with Safe Implementation of Thrombolysis in
Stroke-International Stroke Thrombolysis Register (SITS-
ISTR). Eight patients aged 80 years received IV rtPA
(median age 84, IQR: 83, 87). Of 312 patients with confirmed
acute ischemic stroke admitted to the unit over the 12-month
study period, IV rtPA was given to 8/67 (12%) aged 80
years, compared with 41/245 (17%) of patients aged 80
years. Those over 80 years of age were not significantly less
likely to be treated (Odds ratio 0.67, 95% CIs 0.23 to 1.52,
P0.45 [Fisher exact test]).
Our stroke unit provides both a local comprehensive stroke
service to around 350 000 population, and is a regional
neurosciences center covering 2.5 million people over a wide
geographical area. For patients aged 80, the majority of
referrals came from primary care and already hospitalized
patients (30.5% each). Local and regional emergency depart-
ments accounted for 28% and 11% of referrals, respectively.
This differed from patients aged 80 years, where the referral
sources were emergency departments (72%), primary care
(23%) and inpatients (5%) (2 test; P0.001). Of patients
referred but having contraindications to treatment based on
the European product license, 22/33 (67%) had only age as a
contraindication for referrals from primary care or inpatients,
whereas age was the only factor in 13/49 (26.5%) referred
from emergency departments (P0.001).
Based on our experience, a high proportion of patients may
be excluded from IV rtPA on grounds of age alone. Referral
bias is present, but treatment rates did not differ significantly
from the under 80s in our service for those assessed. The bias
against referral by emergency departments that we saw may
reflect a harsher judgment of functional status in the very
elderly, but does not appear to reflect knowledge or applica-
tion of current license criteria. Discrepancies in baseline
functional status between patients aged 80 and those 80
may explain higher mortality and reduced favorable outcome
in the elderly population. Failure to control for baseline
differences may underestimate the benefit of thrombolysis
with the recognition that hemorrhage rates do not differ
significantly.
The outcomes reported by Berrouschot et al are consistent
with the Canadian Alteplase for Stroke Effectiveness Study
(CASES) series,3 and reflect our own experience. Using
prestroke modified Rankin Scale to adjust for baseline dis-
crepancies, the CASES series found a 16% relative increase in
patients achieving an excellent outcome.3,4 Continued regis-
tration of patients older than 80 in SITS-ISTR will allow
wider analysis.
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Michael T. McCormick, MB, BCh, MRCP (UK)
Keith W. Muir, MD, FRCP (UK)
Division of Clinical Neurosciences
University of Glasgow
Institute of Neurological Sciences
Southern General Hospital
Glasgow, Scotland, UK
1. Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G.
Outcome and severe hemorrhagic complications of intravenous
thrombolysis with tissue plasminogen activator in very old (80 years)
stroke patients. Stroke. 2005;36:2421–2425.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke
Study Group. Tissue plasminogen activator for acute ischemic stroke.
N Engl J Med. 1995;333:1581–1588.
3. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of
the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005;172:
1307–1312.
4. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Inter-
observer agreement for the assessment of handicap in stroke patients.
Stroke. 1988;19:604–607.
Response:
We thank Drs McCormick and Muir for their comments on our
article and the report of their practice with acute stroke treatment
in very old patients, which is very much in line with our own
proceeding. Their results further strengthen the main conclusion
of our study: the outcome of intravenous thrombolysis may be
worse in very old patients, but this is not related to thrombolysis,
but to worse stroke outcome in elderly in general, and to a more
severe initial neurological deficit in the very old patients.
Because the risk of severe hemorrhagic complications is not
increased in very old patients, and even in the very old a notable
number of patients reaches a favorable outcome after
thrombolysis (26% in our study), thrombolytic therapy seems
justified in this increasing stroke population.
In this context, 2 recently published studies are of interest. The
analysis of stroke patients treated with intravenous tPA from a
Swiss databank showed a higher mortality in patients 80 years
(32% versus 12%), whereas the percentage of patients with a
favorable 3-month outcome was comparable between very old
and younger patients (29% versus 37%).1 Moreover, logistic
regression did not identify age as an independent predictor of
outcome in this sample. In another patient series from Texas, the
results were similar with a higher mortality, but comparable rates
of improvement and symptomatic intracerebral hemorrhage in
patients aged 80 years and over.2
In their letter Drs McCormick and Muir addressed the problem
of a potential bias leading to lower referral rates of very old
patients to thrombolysis centers. Such a bias might further
contribute to the lower tPA treatment rates in patients aged 80
and over. In the European BIOMED study of stroke care 30% of
all strokes occurred in the group aged 80 and over.3 In contrast
to this, in the group of tPA treated patients, the proportion of
patients 80 years ranges somewhat lower, between 12% in the
Swiss databank1 and 16% in our study.4 A higher incidence of
contraindications against tPA, such as anticoagulation or severe
comorbidity in older patients, may contribute to lower rates.
However, neither in our study nor in the sample reported by
McCormick and Muir, those aged 80 and older were less likely
to be treated with tPA than younger patients.
To conclude, in a substantial number of patients, age is the
only contraindication against thrombolysis with tPA. A growing
number of studies reported on intravenous thrombolysis in old
and very old patients, and none of these studies provides
evidence to exclude patients from tPA treatment, only because
they have trespassed an arbitrary age limit. Hopefully, results
from ongoing randomized controlled trials will provide more
evidence. Until then, carefully selected very old stroke patients
should not be deferred from intravenous tPA, which is the only
effective acute ischemic stroke therapy.
Go¨tz Thomalla, MD
Klinik und Poliklinik fu¨r Neurologie
Universita¨tsklinikum Hamburg-Eppendorf
Hamburg, Germany
Joachim Ro¨ther, MD
Neurologische Klinik
Klinikum Minden
Universita¨t Hannover
Minden, Germany
Jo¨rg Berrouschot, MD
Neurologische Klinik
Kreiskrankenhaus Altenburg
Altenburg, Germany
1. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A,
Weder B, Muller F, Luthy R, Arnold M, Michel P, Mattle HP, Tettenborn
B, Hungerbuhler HJ, Baumgartner RW, Sztajzel R, Bogousslavsky J,
Lyrer PA. Thrombolysis in stroke patients aged 80 years and older: Swiss
survey of IV thrombolysis. Neurology. 2005;13;65:1795–1798.
2. Chen CI, Iguchi Y, Grotta JC, Garami Z, Uchino K, Shaltoni H, Alex-
androv AV. Intravenous tPA for very old stroke patients. Eur Neurol.
2005;54:140–144.
3. Di Carlo A, Lamassa M, Pracucci G, Basile AM, Trefoloni G, Vanni P,
Wolfe CD, Tilling K, Ebrahim S, Inzitari D. Stroke in the very old:
clinical presentation and determinants of 3-month functional outcome: a
European perspective. European BIOMED Study of Stroke Care Group.
Stroke. 1999;30:2313–2319.
4. Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G.
Outcome and severe hemorrhagic complications of intravenous
thrombolysis with tissue plasminogen activator in very old (80 years)
stroke patients. Stroke. 2005;36:2421–2425.
Economic Benefit of Increasing Utilization of
Intravenous Tissue Plasminogen Activator for
Acute Ischemic Stroke in the United States
To the Editor:
We read with interest the sensitivity analysis on the US
economic benefit possible from increasing utilization of tissue
plasminogen activator in acute stroke by Demaerschalk et al.1
While there are several issues of concern affecting its validity,
we believe their analysis seriously under-represented the present
dollar value of the savings by using a reference value of ()$600
per patient from 1996. After adjusting for the annual effect of
inflation using US Bureau of Labor Statistics Consumer Price
Index data, the actual per treated patient savings is 24% greater,
or ()$745 per patient, in 2005. Using this figure, the best
estimate of cost savings in the first year poststroke ranges from
9 to 90 million dollars, with similar changes in the 95% CI
limits, depending on the proportion of patients receiving tissue
plasminogen activator (see Table below for cost savings per
treatment %).
Estimated US First-Year Post-Stroke Cost Savings by Proportion of Patients Receiving tPA
2% 4% 6% 8% 10% 15% 20%
$9 176 411 $18 352 822 $27 529 233 $36 705 644 $45 882 055 $68 823 083 $91 764 110
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Phillip A. Scott, MD
Robert Silbergleit, MD
Department of Emergency Medicine
University of Michigan
Ann Arbor, Michigan
1. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of
intraveneous tissue plasminogen activator for acute ischemic stroke in the
United States. Stroke. 2005;36:2500–2503.
Response:
Drs Scott and Silbergleit are correct that our estimates of
economic benefit of increasing utilization of intravenous tissue
plasminogen activator (tPA) for acute stroke in the US1 do not
reflect current day savings because our reference values came
from 1996 cost data published in 1998.2 Unfortunately, this
remains the most current US cost-effectiveness study available
for tPA in stroke.
By using the US Department of Labor Bureau of Labor
Statistics Consumer Price Index (CPI) inflation calculator (www.
bls.gov) to adjust for inflation (reference year 1996 and recent
year 2005), the net cost after the first year post-tPA treatment
estimate increases to $756 (95% CI $4384 to $2524) of
savings per treated patient.3 As you have pointed out, this change
would result in $9 314 000 best estimate of cost savings for every
additional 2% of ischemic stroke patients who are thrombolysed
nationwide (see the Table below). Regardless, the inflation-based
revised estimates, to which you refer, remain well within the
published 95% CI.
Unfortunately, this inflation-based correction does not over-
come the fact that the 1998 cost-effectiveness study is becoming
outdated. The values corrected to the annual general inflation
rates assume that the healthcare costs associated with
thrombolysis for stroke have inflated at the same rate. A more
accurate estimate could be derived from gathering updated cost
data associated with the care of acute stroke patients receiving
tPA in 2005 to 2006.
Although we agree that the anticipated cost savings is proba-
bly closer to $9 million, not $7 million, per additional 2%
increase in the national proportion of thrombolysed patients, the
main message remains the same: using tPA for stroke results in
a net cost savings to our healthcare system. This combined with
the clearly favorable health outcomes among tPA-treated patients
supports the continuing efforts to treat a higher proportion of
stroke patients with this drug.
Bart M. Demaerschalk, MD, MSc, FRCPC
Divisions of Cerebrovascular Diseases and
Critical Care Neurology
Department of Neurology
Mayo Clinic College of Medicine
Scottsdale, Arizona
Todd R. Yip, MD, MSc
Department of Physical Medicine and Rehabilitation
University of Saskatchewan
Saskatoon, SK, Canada
1. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of
intravenous plasminogen activator for acute ischemic stroke in the united
states. Stroke. 2005;36:2500–2503.
2. Fagan SC, Morgenstern LB, Petita A, Ward RE, Tilley BC, Marler JR,
Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker
MD. Cost-effectiveness of tissue plasminogen activator for acute ische-
mic stroke. NINDS rt-PA stroke study group. Neurology. 1998;50:
883–890.
3. Price Index (CPI) inflation calculator. US Department of Labor Bureau of
Labor Statistics website. Available at: www.bls.gov. Accessed January 4,
2006.
Hyperglycemia and Hyperinsulinemia
in Circulatory Disorder After
Subarachnoid Hemorrhage
To the Editor:
We read with great interest the recent article by Dr Frontera
and colleagues1 dealing with the relationship between hypergly-
cemia and complications after subarachnoid hemorrhage (SAH).
The results of their study demonstrated that hyperglycemia (the
average peak daily glucose level 105 mg/dL) after SAH was
associated with serious hospital complications, such as conges-
tive heart failure, increased intensive care unit length of stay, and
an increased risk of death or severe disability. The authors
proposed that strict normoglycemic management in patients with
SAH might be important.
Numerous studies have shown that hyperglycemia may ac-
tively participate in the regulation of cellular functions. Bar-
bagallo et al2 showed that hyperglycemia elevated cytosolic free
calcium (Ca) both in myocardial and vascular smooth muscle
cells, suggesting that glucose-related excess intracellular Ca
might be a fundamental lesion in diabetes that contribute to the
elevated blood pressure and cardiac mass in this disease. On the
other hand, it is well recognized that hyperglycemia may be
associated with hyperinsulinemia. Evidence indicates that hyper-
insulinemia might actively participate in the regulation of circu-
latory disorders. Sela et al3 demonstrated that polymorpho-
nuclear leukocytes (PMN) in essential hypertension showed
increased level of intracellular Ca content correlating positively
with the individulal’s blood pressure and plasma insulin. They
proposed that, because PMN priming may lead to oxidative stress
and inflammation, intracellular Ca and insulin are involved in the
pathogenesis of hypertension-induced vascular injury. In a study
we presented earlier, a relationship between membrane fluidity (a
reciprocal value of membrane microviscosity) of erythrocytes
and insulin was investigated in essential hypertension by means
of an electron paramagnetic resonance method.4 It was demon-
strated that the higher the plasma insulin level, the lower the
membrane fluidity of erythrocytes, which might indicate that
hyperinsulinemia might be involved in the regulation of mem-
brane fluidity of erythrocytes. In an in vitro study, we showed
that insulin alone and in combination with Ca decreased the
membrane fluidity of erythrocytes.5 The decreased membrane
fluidity of erythrocytes might cause a disturbance in the blood
rheologic behavior and the microcirculation, which could con-
tribute, at least in part, to the pathophysiology of circulatory
disorders. One hypothesis is that insulin might accelerate abnor-
malities in intracellular Ca-metabolism and membrane function
in blood cells, such as PMN and erythrocytes, which could
partially explain the cardiovascular complications in subjects
with hyperinsulinemia.
In this context, we speculate that abnormal membrane func-
tions associated with hyperglycemia and hyperinsulinemia might
Best Estimates of US Cost Savings in the First Year After Ischemic Stroke by Varying Proportions of
Patients Receiving Intravenous tPA
2% 4% 6% 8% 10% 15% 20%
$9 314 000 $18 628 000 $27 942 000 $37 256 000 $46 570 000 $69 855 000 $93 140 000
Adjusted for annual effect of inflation.
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partially explain the increased complications in patients with
SAH. Therefore, we would like to know whether hyperinsulin-
emia might be related to the complications after SAH. Further
studies should be performed to assess more precisely the mech-
anisms by which hyperglycemia could induce complications in
patients with SAH.
Kazushi Tsuda, MD, FAHA
Division of Cardiology
Department of Medicine
Wakayama Medical University
Wakayama, Japan
1. Frontera JA, Fernandez A, Claassen J, Schmidt M, Schumacher HC,
Wartenberg K, Temes R, Parra A, Ostapkovich ND, Mayer SA. Hyper-
glycemia after SAH: predictors, asscoated complications, and impact on
outcome. Stroke. 2006;37:199–203.
2. Barbagallo M, Shan J, Pang PK, Resnick LM. Glucose-induced alter-
ations of cytosolic free calcium in cultured rat tail artery vascular smooth
muscle cells. J Clin Invest. 1995;95:763–767.
3. Sela S, Shurtz-Swirski R, Farah R, Levy R, Shapiro G, Chezar J, Shasha
SM, Kristal B. A link between polymorphonuclear leukocyte intracellular
calcium, plasma insulin, and essential hypertension. Am J Hypertens.
2002;15:291–295.
4. Tsuda K, Kinoshita Y, Nishio I, Masuyama Y. Hyperinsulinemia is a
dterminant of membrane fluidity of erythrocytes in essential hyper-
tension. Am J Hypertens. 2001;14:419–423.
5. Tsuda K, Kinoshita Y, Nishio I, Masuyama Y. The role of insulin in the
regulation of membrane fluidity of erythrocytes in essential hypertension:
an electron paramagnetic resonance investigation. Am J Hypertens.
2000;13:376–382.
Response:
Dr Tsuda postulates that elevated plasma insulin levels lower
erythrocyte membrane fluidity leading to adverse rheologic
effects and microcirulatory complications. Erythrocyte rigidity
and plasma and whole blood viscosities are higher in animal
models of non–insulin-dependent diabetes mellitus,1 but insulin
itself may further exacerbate these effects by altering intracellu-
lar calcium metabolism. Furthermore, intensive insulin therapy
has been shown to have deleterious effects on retinopathy by
increasing vascular endothelial growth factor gene expression.2
In contrast, since van den Berghe’s landmark article,3 in which
intensive insulin therapy led to substantially reduced mortality
and lowered hospital complications in critically ill patients,
speculation has arisen over whether glycemic control alone was
responsible for these effects or if insulin therapy confers its own
protective benefit. Local administration of insulin has been
shown to increase the availability of -aminobutyric acid
(GABA) and the sensitivity of post-synaptic GABA receptors.
Increased GABA-nergic inhibitory effects may be neuroprotec-
tive4 and indeed, in a separate study, van den Berghe found that
intensive insulin therapy reduced the incidence of seizure in
patients with isolate brain injury.5 Similarly, other nonglycemic
effects of insulin include partial correction of abnormal lipid
profiles and attenuation of the catabolic state present in critical
illness.6
In our recent article7 we did not find an association between
hyperglycemia and vascular complications, such as vasospasm or
cerebral infarction, though others have.8 We were, however,
unable to quantify the amount of insulin our patients received
and cannot directly address the effect of insulin on these vascular
complications. Thus, though it is clear that hyperglycemia is
detrimental in the critically ill, the effects of insulin on endothe-
lial and rheologic function warrant further investigation.
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